(RTTNews) - The following are some of today's top gainers in the pharma/biotech sector.
1. Titan Medical Inc. (TMDI)
Titan Medical is a medical device company focused on the design and development of a robotic surgical system for application in minimally invasive surgery.
Gained 20.64% to close Wednesday's (Apr.10) trading at $2.63.
News: No news
-- Complete the required human confirmatory studies for its SPORT Surgical System under an Investigational Device Exemption during the second half of 2019.
The SPORT Surgical System is a single-port robotic surgical system, being developed for one or more of gynecologic, urologic, colorectal or general abdominal procedures.
--File 510(k) for SPORT Surgical System in the U.S. by year-end 2019. -- File for the CE mark for SPORT Surgical System by year-end 2019.
2. Fulgent Genetics Inc. (FLGT)
Fulgent Genetics is a technology company with a focus on offering comprehensive genetic testing to provide physicians with clinically actionable diagnostic information they can use to improve the quality of patient care.
Gained 20.14% to close Wednesday's trading at $6.80.
News: No news
On February 28, 2019, the Company announced financial results for its fourth quarter and full year ended December 31, 2018.
Non-GAAP loss for the fourth quarter of 2018 was $193,000, or $0.01 per share on revenue of $5.7 million. This compared with a non-GAAP loss of $818,000 or $0.05 per share and revenue of $4.28 million in the year-ago quarter.
The Company ended the year 2018 with cash of $6.74 million.
3. Quorum Health Corporation (QHC)
Quorum Health is a provider of hospital and outpatient healthcare services in its markets across the United States.
Gained 17% to close Wednesday's trading at $1.17.
News: No news
On March 12, 2019, the Company reported financial and operating results for the fourth quarter and year ended December 31, 2018.
Full-year net loss attributable to Quorum Health was $200.2 million, or $6.91 per share on revenue of $1.88 billion. This compared with a net loss attributable to the Company of $114.2 million or $4.06 per share and revenue of $2.07 billion.
Looking ahead to 2019, the Company expects revenue to range between $1.83 billion to $1.88 billion.
4. American Renal Associates Holdings Inc. (ARA)
American Renal Associates is a dialysis services provider in the United States.
Gained 12.25% to close Wednesday's trading at $6.69.
News: No news
On March 8, 2019, the Company announced that it will delay the filing of its Annual Report on Form 10-K for the fiscal year ended December 31, 2018, and the issuance of its earnings release for the fourth quarter and full year 2018. Nevertheless, the Company reported certain preliminary operating data like treatment volume and clinic activity for the fourth quarter and full year 2018.
The Audit Committee of the Board of Directors of the Company is reviewing the Company's revenue recognition methodology and related accounting matters.
5. Guardant Health Inc. (GH)
Guardant Health is a precision oncology company focused on helping conquer cancer through the use of its proprietary blood tests, vast data sets, and advanced analytics.
Gained 11.80% to close Wednesday's trading at $73.99.
News: The Company announced that its liquid biopsy, Guardant360, will be a covered benefit for the members of the health plans associated with eviCore, a technology assessment company.
The eviCore policy is slated to become effective July 1, following which Guardant360 will have added coverage for over 38 million lives in 2019. This will increase total lung cancer coverage for Guardant360 to more than 150 million Americans, including for all Medicare beneficiaries, members of Cigna, Blue Shield of California, UPMC Health Plan, BCBS FEP (Federal Employees Program), and many others, noted the Company.
Guardant Health went public on the Nasdaq Global Select Market, on October 4, 2018, offering its shares at a price of $19.00 each. The stock, which opened at $27.75 in debut trade, had touched an intraday high of $106.58 on March 15, 2019.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.